Hudson Bay Capital Management’s Travere Therapeutics TVTX Stock Holding History

Hudson Bay Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,520	Closed	-$194K	–	1702
2026 Q1	$194K	Buy	+6,520	New	+$195K	﹤0.01%	1109
2024 Q4	–	Sell	-125,000	Closed	-$1.75M	–	1116
2024 Q3	$1.75M	Buy	125,000 +80,439	+181%	+$838K	0.01%	584
2024 Q2	$366K	Buy	+44,561	New	+$300K	﹤0.01%	651
2023 Q3	–	Sell	-444,031	Closed	-$6.82M	–	968
2023 Q2	$6.82M	Buy	+444,031	New	+$8.08M	0.05%	249
2019 Q3	–	Sell	-56,779	Closed	-$1.14M	–	484
2019 Q2	$1.14M	Buy	+56,779	New	+$1.12M	0.03%	320

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hudson Bay Capital Management's TVTX Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 6,520 shares — an estimated $194K sold.

Hudson Bay Capital Management first reported a position in TVTX in Q2 2019 and held it in 5 quarters. The position peaked at $6.82M in Q2 2023. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Hudson Bay Capital Management reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
Hudson Bay Capital Management sold 6,520 Travere Therapeutics shares in Q2 2026, an estimated $194K.
Hudson Bay Capital Management first reported a position in Travere Therapeutics in Q2 2019 and held it in 5 quarters.
Hudson Bay Capital Management's Travere Therapeutics position peaked at $6.82M in Q2 2023.
320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.